期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
18F-FDG PET/CT显像在淋巴瘤肌肉侵犯评价中的价值 被引量:5
1
作者 余思睿 吴湖炳 +4 位作者 王丽娟 任云燕 张胤 陈莉 王全师 《中国老年学杂志》 CAS 北大核心 2019年第19期4692-4696,共5页
目的探讨淋巴瘤肌肉侵犯病灶18氟-脱氧葡萄糖(18F-FDG)正电子发射断位显像/计算机断层显像(PET/CT)的特点,并比较PET和CT对淋巴瘤肌肉侵犯病灶的检测效能。方法回顾性分析34例淋巴瘤肌肉侵犯患者的PET/CT图像特征,并与34例非淋巴瘤患者... 目的探讨淋巴瘤肌肉侵犯病灶18氟-脱氧葡萄糖(18F-FDG)正电子发射断位显像/计算机断层显像(PET/CT)的特点,并比较PET和CT对淋巴瘤肌肉侵犯病灶的检测效能。方法回顾性分析34例淋巴瘤肌肉侵犯患者的PET/CT图像特征,并与34例非淋巴瘤患者的18F-FDG PET/CT肌肉生理性浓聚进行比较。通过分析淋巴瘤肌肉侵犯病灶的PET代谢肿瘤/非肿瘤比值(T/NT ratio)及同病灶CT密度T/NT比值,探讨PET和CT对病灶的探测能力。同时研究淋巴瘤肌肉侵犯与血清乳酸脱氢酶(LDH)及肌酸激酶(CK)水平的关系。结果34例肌肉淋巴瘤患者中,88.2%为非霍奇金淋巴瘤(NHL),11.8%为霍奇金淋巴瘤。其中老年患者的国际预后指数(IPI)及分期更高。70.5%表现为局限性肌肉侵犯,29.5%表现为全身肌肉广泛侵犯。最常累及的肌肉为髂腰肌、腰大肌和臀部肌肉。淋巴瘤肌肉侵犯病灶18F-FDG摄取明显高于肌肉生理性浓聚(t=4.838,P<0.0001)。淋巴瘤肌肉侵犯均未累及头颈部肌肉且79.4%病灶呈现为结节状和块状,而肌肉生理性浓聚52.9%位于头颈部且均表现为沿肌肉走行的条状或片状浓聚。淋巴瘤肌肉侵犯病灶18F-FDG明显高摄取,显示清楚,而在CT上病灶密度改变不明显,难以确认。病灶处PET代谢T/NT比值明显高于CT密度T/NT比值(t=7.515,P<0.0001)。患者的肿瘤侵犯范围及病灶代谢增高程度均与血清LDH和CK水平无相关性(P>0.05)。结论18F-FDG PET/CT能灵敏地、全面地检出淋巴瘤肌肉侵犯病灶,并能很好地与肌肉生理性浓聚相鉴别。淋巴瘤肌肉侵犯的18F-FDG代谢与血浆LDH和CK水平无关。 展开更多
关键词 淋巴瘤 肌肉 18氟-脱氧葡萄糖 正电子发射断位显像/计算机断层显像(PET/CT)
下载PDF
18F-FDG PET/CT在IgG4相关性疾病中的应用 被引量:5
2
作者 杨少习 李洪生 +4 位作者 傅丽兰 黄顺 吴湖炳 王巧愚 王全师 《中国临床医学影像杂志》 CAS 2019年第12期875-880,共6页
目的:探讨18F-FDG PET/CT在IgG4相关性疾病(IgG4-RD)中的应用。方法:本研究回顾性分析47例依据IgG4-RD综合诊断标准诊断为IgG4-RD病例的临床相关信息和18F-FDG PET/CT表现。结果 :47例IgG4-RD中,以男性为主(35/47,74.47%),年龄23~79岁,... 目的:探讨18F-FDG PET/CT在IgG4相关性疾病(IgG4-RD)中的应用。方法:本研究回顾性分析47例依据IgG4-RD综合诊断标准诊断为IgG4-RD病例的临床相关信息和18F-FDG PET/CT表现。结果 :47例IgG4-RD中,以男性为主(35/47,74.47%),年龄23~79岁,平均47.5岁。43例出现多器官受累,以淋巴结(29/47)、胰腺(27/47)及唾液腺(16/47)多见。所有受累病灶均表现为代谢增高,以唾液腺摄取最高(SUVmax为6.44±4.98),其次为淋巴结及胰腺。81.58%的外分泌腺受累患者(31/38)表现为腺体对称性或弥漫性肿胀伴代谢均匀或不均匀性增高。根据血清IgG4是否升高进行分组分析,发现IgG4升高组更容易出现嗜酸性粒细胞升高、前列腺受累,同时受累的泪腺及胰腺摄取程度更高,对激素治疗更敏感(P均<0.05)。41例IgG4-RD有效随访中,65.85%的患者对激素治疗敏感,治疗后血清IgG4下降不明显,但其受累病灶的18F-FDG摄取程度明显降低。结论:PET/CT在IgG4-RD的诊断及鉴别诊断、活检部位的选择、全身脏器受累情况、疗效监测等方面具有重要价值。 展开更多
关键词 免疫球蛋白G 氟脱氧葡萄糖F18 正电子发射断层显像术
下载PDF
^(18)F-FDG PET/CT在脂膜炎性T细胞淋巴瘤中的应用 被引量:1
3
作者 代若雪 傅丽兰 +2 位作者 吴湖炳 王巧愚 李洪生 《中国临床医学影像杂志》 CAS CSCD 2021年第12期894-897,共4页
目的:探讨^(18)F-FDG PET/CT在脂膜炎性T细胞淋巴瘤(SPTCL)诊疗中的应用价值。方法:选择2007年8月—2021年6月经病理确诊为SPTCL且治疗前行^(18)F-FDG PET/CT检查的13例患者,回顾性分析其^(18)F-FDG PET/CT影像学表现(病灶的分布、大小... 目的:探讨^(18)F-FDG PET/CT在脂膜炎性T细胞淋巴瘤(SPTCL)诊疗中的应用价值。方法:选择2007年8月—2021年6月经病理确诊为SPTCL且治疗前行^(18)F-FDG PET/CT检查的13例患者,回顾性分析其^(18)F-FDG PET/CT影像学表现(病灶的分布、大小、最大标准摄取值(SUVmax)等),分析^(18)F-FDG PET/CT影像学表现与IPI评分等临床信息的关系,并初步探讨^(18)F-FDG PET/CT显像对SPTCL疗效评估的价值。结果:^(18)F-FDG PET/CT影像学表现:皮肤受累13例,病变多位于躯干和四肢,SUVmax为8.16±1.66(躯干:6.53±1.32,四肢:3.61±0.32);淋巴结受累6例,最大径为(1.30±0.12) cm,SUVmax为4.74±1.03,最大径与SUVmax呈正相关(P=0.031);骨髓受累7例,SUVmax为4.77±2.92;脾脏受累2例,SUVmax为2.85±0.92;其他脏器受累9例,SUVmax为4.43±0.79。IPI高危组患者9例,病灶SUVmax更高(P=0.035),皮肤受累部位更多(P=0.047)。有效随访6例,完全缓解2例,部分缓解2例,复发2例,其中3例经PET/CT检查后改变治疗方案获得缓解。结论:在^(18)F-FDG PET/CT显像上SPTCL病灶均表现为高代谢,因此^(18)F-FDG PET/CT显像可用于SPTCL的诊断、分期、疗效评价等方面,具有进一步临床推广的应用潜能。 展开更多
关键词 淋巴瘤 T细胞 氟脱氧葡萄糖F18 正电子发射断层显像计算机体层摄影术
下载PDF
^11C-methionine and ^18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas 被引量:11
4
作者 LI Dong-li XU Yi-kai +2 位作者 WANG Quan-shi wu hu-bing LI Hong-sheng 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第1期91-96,共6页
Background ^18F-fluorodeoxyglucose (FDG) is the most widely used radiotracer in tumor imaging,but its use for brain gliomas and recurrence is limited by the high ^18F-FDG uptake in normal brain tissue.^11C-methioni... Background ^18F-fluorodeoxyglucose (FDG) is the most widely used radiotracer in tumor imaging,but its use for brain gliomas and recurrence is limited by the high ^18F-FDG uptake in normal brain tissue.^11C-methionine (MET) has low uptake in the normal brain tissue,providing potential advantages over ^18F-FDG.The aim of the study was to investigate the diagnostic value of ^11C-MET compared to ^18F-FDG positron emission tomography and computed tomography (PET/CT) in patients with suspected primary and residual/recurrent gliomas.Methods Eighty paired PET/CT scans using ^11C-MET and 18F-FDG were performed on 44 newly diagnosed patients with suspected gliomas and 36 post-operative patients with suspected residual/recurrent tumors.PET/CT results were evaluated by visual and semiquantitative analysis.The sensitivity,specificity and accuracy for detection of gliomas and residual/recurrent tumors were calculated using visual analysis.Tumor to contralateral normal gray matter (T/G) ratio was calculated for semiquantitative analysis.Results Final pathology of the 44 newly diagnosed patients included 26 gliomas (14 high-grade and 12 low-grade tumors) and 18 non-glioma benign lesions.Residual/recurrent gliomas were verified in 28 patients and excluded in 8/36 post-operative patients by subsequent histopathologic examination and/or clinical follow-up for more than six months.The sensitivity,specificity and accuracy of 11C-MET PET/CT were 88.5%,83.3% and 86.4% for gliomas and 96.4%,87.5% and 94.4% for residual/recurrent gliomas,respectively.The sensitivity,specificity and accuracy of 18F-FDG PET/CT were 50.0%,88.9% and 65.9% for gliomas and 46.4%,100.0% and 58.3% for residual/recurrent gliomas,respectively.11C-MET had a higher sensitivity than 18F-FDG (83.3% vs.33.3%,P=0.031) in low-grade gliomas,but had no significant difference in sensitivity from 18F-FDG for high-grade gliomas (92.9% vs.64.3%,P=0.219).11C-MET T/G uptake ratios in high-grade gliomas,low-grade gliomas and benign lesions were 1.94±0.53,1.78±0.61 and 1.06±0.34,respectively.18F-FDG T/G uptake ratios in high-grade gliomas,low-grade gliomas and benign lesions were 1.05±0.37,0.66±0.14 and 0.63±0.17,respectively.Conclusions 11C-MET PET/CT is superior to 18F-FDG PET/CT in detecting and delineating gliomas and residual/recurrent tumors,especially low-grade gliomas and residual/recurrent lesions present in gray matter,but its role in non-invasive grading of the tumors is limited. 展开更多
关键词 ^11 C-methionine GLIOMA ^18 F-fluorodeoxyglucose positron emission tomography computed tomography
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部